MiR-181a: a potential biomarker of acute muscle wasting following elective high-risk cardiothoracic surgery

Table 1 Demographic data, co-morbidities and critical care data for non muscle-wasting (n = 19) and muscle-wasting patients (n = 23)

	Non muscle-wasting patients(n = 19)	Muscle-wasting patients (n = 23)	P -value ( t -test, Mann-Whitney^# *, chi-squared)**
Demographic data
Age, years	65.7 ± 17.2	62.0 ± 16.2	0.47
Sex, male/female	9/10	12/11	0.76*
Body mass index, kg/m2^a	26.6 ± 4.6	24.7 ± 4.1	0.18
EuroSCORE	5.3 ± 1.8	5.5 ± 2.6	0.76
Pre-operative creatinine, umol/L^a	81.3 ± 23.6	77.3 ± 17.1	0.52
Pre-operative creatinine clearance, ml/minute^a	84.7 ± 36.1	86.8 ± 34.7	0.66
Pre-operative co-morbidities, n
Ischaemic heart disease	10	8	0.24*
Structural heart disease	9	11	0.97*
Dysrhythmia	2	3	0.80*
Systemic hypertension	7	5	0.94*
Pulmonary hypertension	1	2	0.66*
Hypercholesterolaemia	7	10	0.66*
Congenital cardiac disease	3	6	0.42*
Diabetes	3	1	0.21*
Obstructive lung disease	3	2	0.45*
Outcome data
C-reactive protein day 2	165 ± 60	189 ± 68	0.23
ICU length of stay, days, median (IQR)	1 (1 to 2.5)	2 (1 to 3)	0.62^#
Hospital length of stay, days, median (IQR)	8 (7 to 11)	9 (8 to 10.5)	0.44^#

Data presented as mean ± SD unless otherwise stated. ^aWeight unavailable for two patients in the muscle-wasting group, therefore, n = 21. Data adapted from previously published study [17]. p values calcultated by t-test, # - Man-Whitney or * - Chi-squared as appropriate.

ISSN: 1364-8535